Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has received an average rating of “Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $35.71.

Several equities research analysts have weighed in on DAWN shares. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday. Finally, Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Charles N. York II sold 2,633 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the transaction, the chief financial officer now directly owns 232,485 shares of the company’s stock, valued at approximately $3,254,790. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares in the company, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,248 shares of company stock worth $697,082. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. raised its position in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares in the last quarter. Quest Partners LLC lifted its stake in Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares during the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the second quarter worth about $113,000. Point72 DIFC Ltd acquired a new position in Day One Biopharmaceuticals during the second quarter worth approximately $124,000. Finally, Hsbc Holdings PLC bought a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $163,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN opened at $15.76 on Friday. The stock’s fifty day simple moving average is $14.25 and its 200-day simple moving average is $14.39. Day One Biopharmaceuticals has a 12-month low of $10.90 and a 12-month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. On average, equities analysts anticipate that Day One Biopharmaceuticals will post -0.88 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.